A new therapeutic drug has been developed that can restore or improve cognitive decline in Alzheimer's disease and mild cognitive impairment, as well as renal function decline in chronic kidney disease. 1. Inflammation was the cause of Alzheimer's disease. 2. β-amyloid and other factors were only consequences, not causes. 3. Effects of the novel herbal medicine (RO-8) capable of normalizing inflammation: Cognitive function recovery and improvement rate for Alzheimer's disease and mild cognitive impairment: 90.9% Renal function improvement rate for chronic kidney disease (CKD): 65.5% Patent-pending in the United States, Japan, the EU, and the United Kingdom. ☆UNITED STATES PATENT PATENT NUMBER.: US 10,660,929 B2 ☆UNITED STATES PATENT PATENT NUMBER.: US 11,110,142 B2 ☆EUROPEAN PATENT PATENT NUMBER.: 3545964 ☆JAPANESE PATENT PATENT NUMBER.: 6401414 ☆JAPANESE PATENT PATENT NUMBER.: 6691182 ☆JAPANESE PATENT PATENT NUMBER, : 6154566 A paper on a newly developed Kampo medicine has been published in Current Traditional Medicine following peer review. Author(s): Yoshiteru Shimoide* Volume 12, 2026 Article ID: e22150838396773Pages: 11 DOI: 10.2174/0122150838396773250720081201 New Kampo Improves Cognitive Decline in Alzheimer’s Disease and Mild Cognitive Impairment and Renal Function Decline in Chronic Kidney Disease | Bentham Science 4. The reason why antibody drugs like Donepezil, Reminyl, and Lecanemab—based on the β-amyloid hypothesis—are ineffective has been identified. It was because the hypothesis used to develop these drugs was incorrect. 5. RO-8's anti-inflammatory effect is thought to occur by immunologically converting M1 (inflammatory macrophages) to M2 (anti-inflammatory macrophages). 6. Its efficacy is recognized across all stages of cognitive decline, from mild to severe. 7. Although RO-8 is a new Kampo medicine, it can be used even at this point in time. The person who wants to conduct a supplementary examination may go anytime. Please inform me of these patent rights which wants to obtain the transfer or enforcement right. E-mail: atopic@bridge.ocn.ne.jp Specialism Immunology Board Certified Member of the Japanese Society of Internal Medicine Board Certified Gastroenterologist The Japanese Society of Gastroenterology Board Certified Hepatologist of the Japanese Society of Hepatology Fellow of the Japan Society for Oriental Medicine The last educational background National Defense Medical Collage Recent achievements 2008年5月 欧州皮膚科・性病学会（ＥＡＤＶ）2008 Annual Meetingイスタンブール Atopic dermatitis can be overcome 2009年3月 アメリカアレルギー・喘息・免疫学会議（ＡＡＡＡＩ）2009 Annual Meeting Washington An end to suffering from atopic dermatitis Journal of Allergy and Clinical Immunology. Vol, 123. Issue 2. Supplement, Page S41 アトピー性皮膚炎の87.2％を治癒させ、12.8％を著明改善、及び改善させることが可能であることを示した。 2012年5月 アメリカアレルギー・喘息・免疫学会議（ＡＡＡＡＩ）2012 Annual Meeting Orlando Overturning the conventional notion of bronchial asthma treatment Journal of Allergy and Clinical Immunology. Vol, 129, Issue 2. Supplement. Page AB72. 中等症、および、重症気管支喘息患者の96%を治癒させ得ることを示した。 2015年10月 世界精神病会議（ＷＰＡ）2015 Annual Meeting Vienna Major depressive disorder is an easily cured inflammatory disorder うつ病はサイトカイン病であり、うつ病患者の97.6％を短期間に治癒させることが可能であることを示した